iA Global Asset Management Inc. Lowers Holdings in Danaher Co. (NYSE:DHR)

iA Global Asset Management Inc. reduced its stake in Danaher Co. (NYSE:DHR) by 1.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 517,816 shares of the conglomerate’s stock after selling 5,437 shares during the period. Danaher makes up 1.4% of iA Global Asset Management Inc.’s portfolio, making the stock its 17th biggest position. iA Global Asset Management Inc. owned approximately 0.07% of Danaher worth $129,376,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of DHR. Cary Street Partners Investment Advisory LLC increased its stake in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares in the last quarter. Caden Capital Partners LP increased its position in shares of Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after acquiring an additional 15,313 shares in the last quarter. Legacy Financial Advisors Inc. raised its holdings in Danaher by 2.4% in the 4th quarter. Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock worth $550,000 after acquiring an additional 55 shares during the last quarter. JARISLOWSKY FRASER Ltd lifted its position in Danaher by 10.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after acquiring an additional 55,908 shares in the last quarter. Finally, HighPoint Advisor Group LLC purchased a new stake in Danaher during the 4th quarter valued at $2,614,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR traded up $2.29 during mid-day trading on Friday, reaching $269.31. 4,595,672 shares of the company traded hands, compared to its average volume of 2,803,002. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm has a market cap of $199.47 billion, a PE ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83. The company’s 50 day moving average price is $259.76 and its 200-day moving average price is $254.94. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company posted $2.05 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, equities analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on DHR shares. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. Barclays raised their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Leerink Partners raised their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.